May 4, 2016 – The Institute for Clinical and Economic Review (ICER) will develop two reports assessing the comparative clinical effectiveness and value of new and emerging drug therapies: the first covering non-small cell lung cancer (NSCLC) and the second covering remitting-relapsing multiple sclerosis (MS). Each report will include a systematic review of the comparative clinical effectiveness and cost-effectiveness of selected treatments. Preliminary lists of treatments to be reviewed are included below. Note that these lists are preliminary in nature and are subject to change as the scope of each report develops.

The report assessing therapies for NSCLC will be the subject of a September 2016 meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the report reviewing treatments for MS will be the subject of an October 2016 meeting of the California Technology Assessment Forum (CTAF). During each of the meetings, the independent panel will deliberate and vote on the comparative clinical effectiveness and value of the treatments included in the specified review. The panels will discuss the implications of the votes for policy and practice with a roundtable of experts in the field to provide guidance to patients, clinicians, insurers, and policymakers confronted with decisions on how best to manage the condition under review.

Preliminary scoping documents will be posted to the ICER website in the coming weeks. After the scoping document is posted, stakeholders (including patients, manufacturers, payers, and others) will have one week to submit suggestions and refinements to ensure that the report provides a comprehensive analysis of the considerations and issues of greatest importance.
In order to better accommodate stakeholder input, ICER is in the process of updating our timelines. Specific dates for these reports will be posted by the end of May. Information about the MS review will be available here, and information about the NSCLC review will be available here.

The preliminary lists of drugs to be reviewed are as follows (these lists are preliminary in nature and are subject to change):

Midwest CEPAC: Non-Small Cell Lung Cancer
ICER’s review of NSCLC may include the following approved and emerging therapies:

  • Atezolizumab (Genentech, Inc., Roche Group)
  • Afatinib (Gilotrif®, Boehringer Ingelheim Pharmaceuticals, Inc.)
  • Gefitinib (Iressa®, AstraZeneca)
  • Nivolumab (Opdivo®, Bristol-Meyers Squibb Co.)
  • Pembrolizumab (Keytruda®, Merck & Co.)
  • Erlotinib (Tarceva®, Genentech, Inc. and Astellas Pharma US, Inc.)

Additional information will be posted to the ICER website as it becomes available.

CTAF: Relapsing-Remitting Multiple Sclerosis
ICER’s review of MS may include the following approved and emerging therapies:

  • Daclizumab (Zinbryta™, Biogen and AbbVie, Inc.)
  • Dimethyl fumarate (Tecfidera®, Biogen)
  • Fingolimod (Gilenya®, Novartis Pharmaceuticals, Corp.)
  • Glatiramer acetate (Copaxone®, Teva Neuroscience, Inc.)
  • Interferon beta-1a (Avonex®, Biogen)
  • Interferon beta-1a (Rebif®, EMD Serono. Inc.)
  • Interferon beta-1b (Betaseron®, Bayer)
  • Natalizumab (Tysabri®, Biogen)
  • Ocrelizumab (Ocrevus™, Genentech, Inc., Roche Group)
  • Rituximab (Rituxan®, Genentech, Inc., Roche Group)

Additional information will be posted to the ICER website as it becomes available.